This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Powell, C. B. Articles by Ziegler, J. Search for Related Content PubMed PubMed Citation Articles by Powell, C. B. Articles by Ziegler, J.

Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers: Role of Serial Sectioning in the Detection of Occult Malignancy

From the Gynecologic Oncology Program and Cancer Risk Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA

Address reprint requests to John L. Ziegler, MD, MSc, PO Box 0808, UCSF Comprehensive Cancer Center, 2340 Sutter Street, Room N424, San Francisco, CA 94143; e-mail: ziegler{at}itsa.ucsf.edu

PURPOSE: Women who carry deleterious mutations of BRCA1 or BRCA2 genes have up to a 54% lifetime risk of developing ovarian cancer. After childbearing, women at high risk increasingly choose bilateral risk-reducing salpingo-oophorectomy (RRSO). Two recent studies of BRCA mutation carriers reported occult malignancy in 2.5% of women undergoing RRSO. This study aimed to increase this detection rate using a protocol.

METHODS: In 1996, the University of California San Francisco Gynecologic Oncology Program instituted a surgical-pathologic RRSO protocol that was composed of complete removal and serial sectioning of both ovaries and fallopian tubes, peritoneal and omental biopsies, and collection of peritoneal washings for cytology. We report the pathologic findings in 67 BRCA mutation carriers according to the degree of adherence to this protocol.

RESULTS: Of the 67 procedures, the protocol was followed completely or partially in 41 (61%). Seven occult malignancies were discovered, four in the fallopian tube and three in the ovaries. Six of these were microscopic, and all seven (17%) were found in specimens from complete or partial protocol procedures as opposed to standard procedures (P = .026). Other variables such as age, parity, BRCA1 or BRCA2 mutation, or type of surgery did not alter the strong effect of protocol procedure on the cancer detection rate.

CONCLUSION: A rigorous operative and pathologic protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation carriers nearly seven-fold. If confirmed, this finding will alter postoperative management because additional staging, chemotherapy, and follow-up may be necessary in affected women.

Preliminary results of this study were presented at the Western Association of Gynecologic Oncologists, Steamboat Springs, CO, June 28-29, 2003.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. J. Callahan, C. P. Crum, F. Medeiros, D. W. Kindelberger, J. A. Elvin, J. E. Garber, C. M. Feltmate, R. S. Berkowitz, and M. G. Muto Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction J. Clin. Oncol., September 1, 2007; 25(25): 3985 - 3990. [Abstract] [Full Text] [PDF]

				N. D. Kauff and R. R. Barakat Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2 J. Clin. Oncol., July 10, 2007; 25(20): 2921 - 2927. [Abstract] [Full Text] [PDF]

				L.-m. Chen, K. Y. Yang, S. E. Little, M. K. Cheung, and A. B. Caughey Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families Obstet. Gynecol., July 1, 2007; 110(1): 18 - 25. [Abstract] [Full Text] [PDF]

				B. Y. Karlan, A. Berchuck, and D. Mutch The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice Obstet. Gynecol., July 1, 2007; 110(1): 155 - 167. [Abstract] [Full Text] [PDF]

				C. P. Crum, R. Drapkin, D. Kindelberger, F. Medeiros, A. Miron, and Y. Lee Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer Clin. Med. Res., March 1, 2007; 5(1): 35 - 44. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes J. Clin. Oncol., October 1, 2006; 24(28): 4642 - 4660. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes Ann. Surg. Oncol., October 1, 2006; 13(10): 1296 - 1321. [Abstract] [Full Text] [PDF]

				K. M. Schmeler, C. C. Sun, D. C. Bodurka, K. G. White, P. T. Soliman, A. R. Uyei, J. L. Erlichman, B. K. Arun, M. S. Daniels, S. A. Rimes, et al. Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstet. Gynecol., September 1, 2006; 108(3): 515 - 520. [Abstract] [Full Text] [PDF]

				A. Finch, M. Beiner, J. Lubinski, H. T. Lynch, P. Moller, B. Rosen, J. Murphy, P. Ghadirian, E. Friedman, W. D. Foulkes, et al. Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation JAMA, July 12, 2006; 296(2): 185 - 192. [Abstract] [Full Text] [PDF]

				I. Cass, C. Holschneider, N. Datta, D. Barbuto, A. E. Walts, and B. Y. Karlan BRCA-Mutation-Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? Obstet. Gynecol., December 1, 2005; 106(6): 1327 - 1334. [Abstract] [Full Text] [PDF]

				W. S. Rubinstein Surgical Management of BRCA1 and BRCA2 Carriers: Bitter Choices Slightly Sweetened J. Clin. Oncol., November 1, 2005; 23(31): 7772 - 7774. [Full Text] [PDF]